Previous studies have demonstrated that using the combination of ET to a single anti-HER2 blockade with trastuzumab (TAnDEM and eLEcTRA) or lapatinib (EGF30008) in HR-positive/HER2-positive metastatic BC led to better clinical outcomes compared with ET alone [60,61,62]. This evidence concerns the gene ERBB2 and breast cancer.